Retension Pharmaceuticals, Inc. has announced the appointment of Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026. The company’s Board of Directors approved the appointment, which is effective as of the Commencement Date.
Mr. Wong brings 30 years of experience in management and controllership. His most recent role was as Vice President of Accounting at The Save Mart Companies, a regional grocery chain. Prior to that, he served as Vice President and Chief Accounting Officer at Cytokinetics, Inc. (NASDAQ: CYTK) from 2019 to 2024. Earlier in his career, he held roles at Genentech, Inc., culminating in the position of Controller and Chief Accounting Officer. Mr. Wong began his career as an audit manager at Ernst & Young LLP and holds a Bachelor of Science in Business Administration from the University of California, Berkeley.
The appointment is governed by an Offer Letter. The compensation package includes an annual base salary of $360,000. Mr. Wong is eligible for a discretionary bonus with a target opportunity equal to 30% of his base salary, which may be paid in cash or equity and will be prorated for 2026. He is also receiving a sign-on bonus of $20,000, contingent upon continued employment through March 31, 2027. Additionally, he was granted a stock option award for 25,000 shares of the company’s common stock. This award vests 25% on the first anniversary of the Commencement Date, with the remaining balance vesting in thirty-six monthly increments.
Mr. Wong will also be eligible to participate in the company’s Executive Change in Control and Severance Plan. The filing confirms there are no family relationships between Mr. Wong and the company’s directors or executive officers, nor are there any arrangements or understandings regarding the appointment.
